Capitolul 11 - BIBLIOGRAFIE - Ghid din 2009 PENTRU ÎNGRIJIREA PACIENŢILOR CU DIABET ZAHARAT 2016
M.Of. 608 bis
Ieşit din vigoare Versiune de la: 10 Martie 2016
CAPITOLUL 11:BIBLIOGRAFIE
1.World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva, 1999.
2.Diabetes Atlas-Executive Summary. International Diabetes Federation, 2003.
3.Inzucchi ES, Bergenstal MR, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care, 6:1364-1379, 2012
Republicat în limba română în Romanian Journal of Diabetes, Nutrition & Metabolic Diseases, vol. 20, supl. 1, 2013, pag. 219-246.
a)Inzucchi ES, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient Centered Approach.
Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care; 38; pag 140-149; 2015
4.Christensen NK, Williams P, Pfister R. Cost savings and clinical effectiveness of an extension service diabetes program. Diabetes Spectrum, 17: 171-175, 2004.
5.Mortimer D, Kelly J. Economic evaluation of the good life club intervention for diabetes self-management. Australian Journal of Primary Health, 12:91-100, 2006.
6.American Diabetes Association. A position statement of American Diabetes Association, Diabetes Care 36: Supplement 1 S11-S66, 2013.
7.International Association of Dabetes and Pregnancy Study Groups Consensus panel. International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy. Diabetes Care, 33: 676-682, 2010.
8.Alberti M, Zimmet P, Shaw, Internationl Diabetes Federation: a consensus on Type 2 diabetes prevention. DIABETIC Meddicine 24: 451-463, 2007.
9.Knowler WC, et al., "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, " N. Engl. J. Med, 346: 393-403, 2002.
10.Nathan DM, Davidson MB, DeFronzo RA et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care, 30: 753-759, 2007.
11.Buchmanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes, 51:v2796-803, 2001.
12.Durbin RJ. Thiazolidinedione therapy in the prevention of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes, Obesity and Metabolism, 6:280-5, 2004.
13.TorgersonJS, Hauptman J, Boldrin MN et al. XENICAL in the Prevention of Diabetes in Obese Subjects Study. Diabetes Care, 27:155-61, 2004.
14.Hâncu N, Romanian Diabetes Epidemics Programme (EPIDIAB). 37 th EASD Congress, Glasgow, 2001.
15.Manson JE, Ajani UA, Liu S, et al. A Prospective Study of Cigarette Smoking and the Incidence of Diabetes Mellitus Among US Male Physicians. Am J Med. 109: 538-542, 2000.
16.Targher G, Alberiche M, Zenere MB, Bonadonna RC, Muggeo M, Bonora E: Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 82:3619-3624, 1997.
17.K. Reynolds, A. Liese, S. Daniels et al, Smoking and Cardiobascular Risk Factors in Youth with Diabetes, Diabetes Suppl 57 A288, 2008.
18.Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal, 321: 405-412, 2000.
19.Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Annals of Internal Medicine, 141: 421-431, 2004.
20.Gerstein HC, Pogue J. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia, 48: 1749-1755, 2005.
21.American Diabetes Association. A position statement of American Diabetes Association, Diabetes Care 3: S5-S65, 2010.
22.Kitzmiller JL et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care, 31: 1060-1079, 2008.
23.Sarol JN, Nicodemus NA, Tan KM et al. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966-2004). Current Medical Research & Opinion, 21: 173-184, 2005.
24.Welschen LM, Bloemendal E, Nijpels G et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care, 28: 1510-1517, 2005.
25.Welschen LM, Bloemendal E, Nijpels G et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin. Cochrane Database of Systematic Reviews (2):CD005060, 2005.
26.Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Current Medical Research & Opinion, 22: 671-681, 2006.
27.Farmer A, Wade A, French DP et al. The DiGEM trial protocol: a randomised controlled trial to determine the effect on glycaemic control of different strategies of blood glucose self-monitoring in people with type 2 diabetes. BMC Family Practice 6(25), 2005
28.Moreland EC, Volkening LK, Lawlor MT et al. Use of a blood glucose monitoring manual to enhance monitoring adherence in adults with diabetes: a randomized controlled trial. Archives of Internal Medicine, 166: 689-695, 2006.
29.Siebolds M, Gaedeke O, Schwedes U et al. Self-monitoring of blood glucose - psychological aspects relevant to changes in HbA1c in type 2 diabetic patients treated with diet or diet plus oral antidiabetic medication. Patient Education & Counseling, 62: 104-110, 2006.
30.Karter AJ, Chan J, Parker MM et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care, 29(8).260, 2006.
31.DCCT New England Journal of Medicine, 329(14), September 30, 1993.
32.Nathen DM, Buse JB, Davison MB et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 8 1963-1972, 2006.
33.Aschner P et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab, 12:252-261, 2010.
34.National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care (CG34). London: NICE, 2006.
35.Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine 339: 229-234, 1998.
36.Eddy DM, Schlessinger L. Validation of the archimedes diabetes model. Diabetes Care 26: 3102-3110, 2002.
37.Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabetic Medicine, 21: 238-245, 2004.
38.Stephens JW, Ambler G, Vallance P et al. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? European Journal of Cardiovascular Prevention and Rehabilitation, 11: 521-528, 2004.
39.Guzder RN, Gatling W, Mullee MA et al. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabetic Medicine, 22: 554-562, 2005.
40.Coleman RL, Stevens RJ, Renakaran R et al. Framington, SCORE and DECODE do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care, 30: 1292-1293, 2007.
41.Stevens RJ, Kothari V, Adler AI et al. The UKPDS risk engine: a model for the risk of coronary heart diseasein type II diabetes (UKPDS 56). Clinical Science, 101: 671-679, 2001.
42.Tuomilehto J, Rastenyte D. Epidemiology of macrovascular disease and hypertension in diabetes mellitus.International textbook of diabetes mellitus, 2nd edn. Chichester: John Wiley, 1559-1583, 1997.
43.Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. 366: 1267-1278, 2005.
44.Vijan S, Hayward RA, American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Annals of Internal Medicine, 140: 650-658, 2004.
45.National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events inpatients at increased risk of developing cardiovascular disease or those with established cardiovascular disease (TA94). London: NICE, 2006.
46.National Institute for Health and Clinical Excellence. Ezetimibe for the treatment of primary (heterozygousfamilial and non-familial) hypercholesterolaemia (TA132). London: NICE, 2007.
47.Insull W, Kafonek S, Goldner D et al. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. American Journal of Cardiolog, 87: 554-559, 2001.
48.Van Venrooij FV, van de Ree MA, Bots ML et al. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care, 25: 1211-1216 2002.
49.Miller M, Dobs A, Yuan Z et al. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. Current Medical Research & Opinion, 20: 1087-1094, 2004.
50.Berne C, Siewert DA, URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovascular Diabetology, 4:7, 2005.
51.Colhoun HM, Betteridge DJ, Durrington PN et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 48: 2482-2485, 2005.
52.Sever PS, Poulter NR, Dahlof B et al. Reduction in cardiovascular events with atorvastatin in 2, 532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial - lipid-lowering arm (ASCOT-LLA), Diabetes Care, 28: 1151-1157, 2005.
53.Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care, 29: 1220-1226, 2006.
54.Steiner G, Hamsten A, Hosking J et al. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet, 57: 905-910, 2001.
55.Vakkilainen J, Steiner G, Ansquer JC et al. Relationships between low- density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation, 107: 1733-1737, 2003.
56.Keech A, Simes R, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet, 2005.
57.Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet, 364: 331-337, 2004.
58.Bhatt DL, Marso SP, Hirsch AT et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. American Journal of Cardiology, 90: 625-628, 2002.
59.Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST- segment elevation. New England Journal of Medicine, 345: 494-502, 2001.
60.Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine, 354: 1706-1717, 2006.
61.Steinhubl SR, Berger PB, Mann JT III et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. The Journal of the American Medical Association, 288: 2411-2420, 2002.
62.Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by longterm therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 358: 527-533, 2001.
63.Younis N, Broadbent DM, Vora JP et al. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet, 361: 195-200, 2003.
64.Jose VM, Bhansali A, Hota D et al. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabetic Medicine, 24(4):377-383, 2007.
65.Raskin J, Smith TR, Wong K et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. Journal of Palliative Medicine, 9: 29-40, 2006.
66.Raskin J, Pritchett YL, Wang F et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Medicine, 6(5):346-356, 2005.
67.Goldstein DJ, Lu Y, Detke MJ et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain, 116: 109-118, 2005.
68.Hardy T, Sachson R, Shen S et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care, 30: 21-26, 2007.
69.Gomez-Perez FJ, PerezMonteverde A, Nascimento O et al. Gabapentin for the treatment of painful diabetic neuropathy: dosing to achieve optimal clinical response. British Journal of Diabetes & Vascular Disease, 4: 173-178, 2004.
70.Richter RW, Portenoy R, Sharma U et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo- controlled trial. Journal of Pain, 6: 253-260, 2005.
71.Rosenstock J, Tuchman M, Lamoreaux L et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain, 110: 628-638, 2004.
72.Harvey JN. Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. Current Opinion in Nephrology & Hypertension, 12: 317-322, 2003.
73.Banerjee S, Ghosh US, Saha SJ. Role of GFR estimation in assessment of the status of nephropathy in type 2 diabetes mellitus. Journal of the Association of Physicians of India, 53:181-4, 2005.
74.Baskar V, Venugopal H, Holland MR et al. Clinical utility of estimated glomerular filtration rates in predicting renal risk in a district diabetes population. Diabetic Medicine, 23: 1057-1060, 2006.
75.Cortes SL, Martinez RH, Hernandez JL et al. Utility of the Dipstick Micraltest II in the screening of microalbuminuria of diabetes mellitus type 2 and essential hypertension. Revista de Investigacion Clinica, 58: 190-197, 2006.
76.Incerti J, Zelmanovitz T, Camargo JL et al. Evaluation of tests for microalbuminuria screening in patients with diabetes. Nephrology Dialysis Transplantation, 20: 2402-2407, 2005.
77.MacIsaac RJ, Tsalamandris C, Panagiotopoulos S et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care, 27:1 95-200, 2004.
78.Middleton RJ, Foley RN, Hegarty J et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrology Dialysis Transplantation, 21: 88-92, 2006.
79.Parikh CR, Fischer MJ, Estacio R et al. Rapid microalbuminuria screening in type 2 diabetes mellitus: simplified approach with Micral test strips and specific gravity [erratum appears in Nephrol DialTransplant, 19: 2425, 2004].
80.Poggio ED, Wang X, Greene T et al. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. Journal of the American Society of Nephrology, 16: 459-466, 2005.
81.Rigalleau V, Lasseur C, Perlemoine C et al. A simplified Cockcroft- Gault formula to improve the prediction of the glomerular filtration rate in diabetic patients. Diabetes & Metabolism, 32: 56-62, 2006.